Aclaris Therapeutics Inc (ACRS):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Aclaris Therapeutics Inc (ACRS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9424
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:72
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Aclaris Therapeutics Inc (Aclaris Therapeutics) is a dermatologist-led bio-pharmaceutical company which focuses on identifying, developing, and commercializing prescription drug products for unmet needs in aesthetic and medical dermatology as well as immunology. Its lead product, ESKATA, is a proprietary formulation of high-concentration hydrogen peroxide topical solution prescribed for the treatment of raised seborrheic keratosis (SK). The company’s pipeline products include A-101, ATI-502, ATI-501, ATI-450-MK-2 inhibitor, soft JAK inhibitor, ITK oral anti-IL17 and ITK topical anti-IL17. Aclaris Therapeutics’ pipeline products are used for the treatment of common warts, alopecia areata, androgenetic alopecia, psoriasis, arthritis, gangrenosum, inflammatory skin diseases, atopic dermatitis and others. The company also develops investigational drugs to treat skin and hair conditions. Aclaris Therapeutics is headquartered in Wayne, Pennsylvania, the US.

Aclaris Therapeutics Inc (ACRS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Aclaris Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Aclaris Therapeutics to Acquire Worldwide Rights of RHOFADE from Allergan Sales 13
Venture Financing 14
Confluence Life Sciences Raises USD4.8 Million in Financing 14
Aclaris Therapeutics Raises USD40 Million in Series C Financing 15
Confluence Life Sciences Raises USD2.4 Million in Post Seed Financing Round 17
Aclaris Therapeutics Raises USD21 Million in Series B Venture Financing 18
Confluence Life Sciences Raises Funds Through Venture Financing 19
Confluence Life Sciences Secures USD0.5 Million in Series A Funding Round 20
Aclaris Therapeutics Raises US$21 Million In Series A Financing 21
Confluence Life Sciences Raises US$4 Million In Series A Financing 23
Partnerships 24
Aclaris Therapeutics Enters Into Licensing Agreement with JAKPharm and Key Organics 24
Licensing Agreements 25
Cipher Pharma Enters into Licensing Agreement with Aclaris Therapeutics 25
Vixen Pharma Enters into Licensing Agreement with Columbia University 26
Aclaris Therapeutics International Enters into Licensing Agreement with Rigel Pharma 27
Equity Offering 28
Aclaris Therapeutics Raises USD106.9 Million in Public Offering of Shares 28
Aclaris Therapeutics Raises USD86.3 Million in Public Offering of Shares 30
Aclaris Therapeutics Raises USD20 Million in Public Offering of Shares 32
Aclaris Therapeutics Raises USD104.7 Million in Public Offering of Shares 33
Aclaris Therapeutics Raises USD20 Million in Private Placement of Shares 35
Aclaris Therapeutics Raises USD63.3 Million in IPO 36
Acquisition 38
Aclaris Therapeutics Acquires Confluence Life Sciences 38
Aclaris Therapeutics to Acquire Vixen Pharma 39
Aclaris Therapeutics Inc – Key Competitors 40
Aclaris Therapeutics Inc – Key Employees 41
Aclaris Therapeutics Inc – Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Recent Developments 43
Financial Announcements 43
Aug 03, 2018: Aclaris Therapeutics reports second quarter 2018 financial results and provides update on clinical and commercial developments 43
May 08, 2018: Aclaris Therapeutics Reports First Quarter 2018 Financial Results and Provides Update on Clinical and Commercial Developments 46
Mar 12, 2018: Aclaris Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results 49
Nov 07, 2017: Aclaris Therapeutics Reports Third Quarter 2017 Financial Results 53
Aug 08, 2017: Aclaris Therapeutics Reports Second Quarter 2017 Financial Results 57
May 09, 2017: Aclaris Therapeutics Reports First Quarter 2017 Financial Results 59
Mar 15, 2017: Aclaris Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 61
Corporate Communications 63
Jun 15, 2018: Aclaris Therapeutics Appoints Dr. David Gordon As Chief Medical Officer 63
Apr 24, 2018: Aclaris Therapeutics Announces Names Bryan Reasons As Director And Chairman Of Audit Committee 64
Aug 09, 2017: Aclaris Announces Appointment of Andrew Schiff to Board of Directors 65
Jan 26, 2017: Aclaris Therapeutics Announces Appointment of Andrew Powell to Board of Directors 66
Product News 67
05/15/2018: Aclaris Therapeutics to Support Symposium on JAK Inhibitors at the International Investigative Dermatology 2018 Meeting 67
04/24/2017: Aclaris Therapeutics Hosts Symposium on JAK Inhibitors at the 76th Annual Society for Investigative Dermatology Meeting 68
Product Approvals 69
Aug 02, 2017: Aclaris Therapeutics Submits Investigational New Drug Application for ATI-50002 to Treat Alopecia Areata 69
Clinical Trials 70
Dec 19, 2017: Aclaris Therapeutics Initiates a Pilot Clinical Trial to Study ATI-50002 Topical in Patients with Vitiligo 70
May 05, 2017: Aclaris Therapeutics Completes Phase 1 Clinical Trial of ATI-50001 for the Treatment of Alopecia Universalis and Alopecia Totalis 71
Appendix 72
Methodology 72
About GlobalData 72
Contact Us 72
Disclaimer 72

List of Tables
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aclaris Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Aclaris Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Aclaris Therapeutics to Acquire Worldwide Rights of RHOFADE from Allergan Sales 13
Confluence Life Sciences Raises USD4.8 Million in Financing 14
Aclaris Therapeutics Raises USD40 Million in Series C Financing 15
Confluence Life Sciences Raises USD2.4 Million in Post Seed Financing Round 17
Aclaris Therapeutics Raises USD21 Million in Series B Venture Financing 18
Confluence Life Sciences Raises Funds Through Venture Financing 19
Confluence Life Sciences Secures USD0.5 Million in Series A Funding Round 20
Aclaris Therapeutics Raises US$21 Million In Series A Financing 21
Confluence Life Sciences Raises US$4 Million In Series A Financing 23
Aclaris Therapeutics Enters Into Licensing Agreement with JAKPharm and Key Organics 24
Cipher Pharma Enters into Licensing Agreement with Aclaris Therapeutics 25
Vixen Pharma Enters into Licensing Agreement with Columbia University 26
Aclaris Therapeutics International Enters into Licensing Agreement with Rigel Pharma 27
Aclaris Therapeutics Raises USD106.9 Million in Public Offering of Shares 28
Aclaris Therapeutics Raises USD86.3 Million in Public Offering of Shares 30
Aclaris Therapeutics Raises USD20 Million in Public Offering of Shares 32
Aclaris Therapeutics Raises USD104.7 Million in Public Offering of Shares 33
Aclaris Therapeutics Raises USD20 Million in Private Placement of Shares 35
Aclaris Therapeutics Raises USD63.3 Million in IPO 36
Aclaris Therapeutics Acquires Confluence Life Sciences 38
Aclaris Therapeutics to Acquire Vixen Pharma 39
Aclaris Therapeutics Inc, Key Competitors 40
Aclaris Therapeutics Inc, Key Employees 41
Aclaris Therapeutics Inc, Subsidiaries 42

List of Figures
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Aclaris Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Aclaris Therapeutics Inc (ACRS):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Veritas (India) Ltd:企業の戦略・SWOT・財務情報
    Veritas (India) Ltd - Strategy, SWOT and Corporate Finance Report Summary Veritas (India) Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Akonni Biosystems Inc:企業の製品パイプライン分析2018
    Summary Akonni Biosystems Inc (Akonni Biosystems) is a molecular diagnostics company that develops, manufactures, and distributes integrated molecular diagnostic systems. The company provides product such as nucleic acid extraction kits, molecular diagnostic tests, thermal cyclers, microarray reader …
  • Titan Machinery Inc. (TITN):企業の財務・戦略的SWOT分析
    Titan Machinery Inc. (TITN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Hunan Corun New Energy Co Ltd (600478):電力:M&Aディール及び事業提携情報
    Summary Hunan Corun New Energy Co Ltd (Corun) is a battery manufacturing company that designs, research's, produces and commercializes materials and batteries. The company develops high quality energy materials, extension products and advanced batteries, among others. It also manufactures ultra-inte …
  • Electricidade de Mocambique EP:企業の戦略的SWOT分析
    Electricidade de Mocambique EP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • The Broad Institute Inc-製薬・医療分野:企業M&A・提携分析
    Summary The Broad Institute Inc (Broad Institute), a subsidiary of The Broad Foundation, is a non-profit research organization that meets critical challenges in biology and medicine. The institute transforms medicine by utilizing systematic approaches in biological sciences, to speed up the understa …
  • LT Group, Inc. (LTG):企業の財務・戦略的SWOT分析
    LT Group, Inc. (LTG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Adani Enterprises Ltd (ADANIENT)
    Adani Enterprises Ltd (ADANIENT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • SNGN Romgaz SA (SNG):石油・ガス:M&Aディール及び事業提携情報
    Summary SNGN Romgaz SA (Romgaz), formerly Societatea Nationala de Gaze Naturale Romgaz SA, is an oil and gas company which explores, produces and supplies natural gas. The company's activities include exploration of petroleum onshore and offshore, natural gas production, electric power production, t …
  • Real Matters Inc (REAL):企業の財務・戦略的SWOT分析
    Real Matters Inc (REAL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • RentPath, LLC:企業の戦略・SWOT・財務分析
    RentPath, LLC - Strategy, SWOT and Corporate Finance Report Summary RentPath, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Centers for Disease Control and Prevention-製薬・医療分野:企業M&A・提携分析
    Summary Centers for Disease Control and Prevention (CDC), a subsidiary of US Department of Health and Human Services is a public health institute that offers health, safety and security threat management solutions. The institute provides health information to fight diseases and support communities f …
  • AusNet Services Ltd (AST):企業の財務・戦略的SWOT分析
    AusNet Services Ltd (AST) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • AvidBiotics Corp-製薬・医療分野:企業M&A・提携分析
    Summary AvidBiotics Corp (AvidBiotics) is a healthcare company that develops non-antibody proteins targeting cancer, bacteria and virus-infected cells. The company develops a portfolio of therapeutic protein candidates and protein engineering platforms which include avidocin proteins, mica-body prot …
  • Turk Hava Yollari Anonim Ortakligi:戦略・SWOT・企業財務分析
    Turk Hava Yollari Anonim Ortakligi - Strategy, SWOT and Corporate Finance Report Summary Turk Hava Yollari Anonim Ortakligi - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Magellan Midstream Partners, L.P.:企業の戦略・SWOT・財務情報
    Magellan Midstream Partners, L.P. - Strategy, SWOT and Corporate Finance Report Summary Magellan Midstream Partners, L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Nisshinbo Holdings Inc (3105):企業の財務・戦略的SWOT分析
    Nisshinbo Holdings Inc (3105) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Beerenberg Corp. AS:企業の戦略的SWOT分析
    Beerenberg Corp. AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Aerostar S.A.:企業の戦略・SWOT・財務情報
    Aerostar S.A. - Strategy, SWOT and Corporate Finance Report Summary Aerostar S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Pension Insurance Corporation plc:企業の戦略・SWOT・財務情報
    Pension Insurance Corporation plc - Strategy, SWOT and Corporate Finance Report Summary Pension Insurance Corporation plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆